Vaccination

Novel HIV vaccine trial starts at Oxford

The University of Oxford today started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.

Vaccination

Pfizer COVID-19 vaccine protective against SARS-CoV-2 variants

The Pfizer COVID-19 vaccine is protective against several SARS-CoV-2 variants that have emerged, according to new research presented in the journal mBio, an open-access journal of the American Society for Microbiology. While ...

HIV & AIDS

Four decades on, where's the HIV vaccine?

In the four decades since the first cases of what would come to be known as AIDS were documented, scientists have made huge strides in HIV treatment, transforming what was once a death sentence to a manageable condition.

HIV & AIDS

Vaccine regimen fails to prevent HIV-1 infection in South Africa

(HealthDay)—A canarypox-protein HIV vaccine regimen (ALVAC-HIV) plus bivalent subtype C gp120-MF59 adjuvant does not prevent HIV-1 infection among adults in South Africa, according to a study published in the March 25 issue ...

Diseases, Conditions, Syndromes

Novavax COVID-19 vaccine news welcomed in South Africa

News that the Novavax COVID-19 vaccine has shown about 60% efficacy on HIV-positive patients and that it seems to work against the variant of the virus now dominant in South Africa is being welcomed with relief in the country, ...

page 6 from 27